Table 4.
Univariate analysis for overall survival and progression free survival in high-intermediate and high risk IPI patients
| Median OS, months | HR (95% CI) | P-value | Median PFS, months | HR (95% CI) | P-value | |
|---|---|---|---|---|---|---|
| Age | ||||||
| < 60 years | 7.0 | 0.79 (0.39-1.61) | 0.512 | 2.9 | 0.50 (0.24-1.01) | 0.059 |
| ≥ 60 years | 9.2 | 9.6 | ||||
| Gender | ||||||
| Male | 10.1 | 1.33 (0.64-2.76) | 0.444 | 8.1 | 1.07 (0.29-2.29) | 0.862 |
| Female | 5.2 | 3.5 | ||||
| Performance status | ||||||
| 0-1 | 10.1 | 1.72 (0.79-3.73) | 0.168 | 8.1 | 1.15 (0.51-2.59) | 0.728 |
| 2-4 | 4.8 | 3.6 | ||||
| B symptom | ||||||
| Absent | 9.2 | 1.29 (0.62-2.66) | 0.490 | 8.1 | 1.09 (0.51-2.33) | 0.810 |
| Present | 7.0 | 3.6 | ||||
| Stage | ||||||
| 1-2 | 4.0 | 0.21(0.02-0.72) | 0.147 | 3.6 | 0.45 (0.05-3.44) | 0.445 |
| 3-4 | 9.2 | 8.1 | ||||
| Extranodal involvement | ||||||
| 0-1 | 10.1 | 1.13 (0.56-2.28) | 0.729 | 14.7 | 1.27 (0.61-2.67) | 0.518 |
| ≥ 2 | 8.1 | 3.9 | ||||
| Bone marrow involvement | ||||||
| Negative | 11.9 | 1.33 (0.66-2.67) | 0.414 | 9.5 | 1.29 (0.64-2.61) | 0.467 |
| Positive | 7.3 | 7.0 | ||||
| LDH | ||||||
| Normal | 9.2 | 1.51 (0.45-4.97) | 0.498 | 8.1 | 1.54 (0.46-5.10) | 0.474 |
| Elevated | 7.6 | 7.3 | ||||
| PIT | ||||||
| Group 1-2 | 16.9 | 1.35 (0.58-3.14) | 0.476 | 8.1 | 1.06 (0.45-2.48) | 0.883 |
| Group 3-4 | 7.6 | 7.3 | ||||
| ALC | ||||||
| ≥ 1.0 × 109/l | 10.6 | 3.09 (1.52-6.32) | 0.002 | 11.9 | 4.02 (1.80-8.97) | 0.001 |
| < 1.0 × 109/l | 4.0 | 2.9 |
LDH, lactate dehydrogenase; IPI, International Prognostic Index; L, low; LI, low-intermediate; HI, high-intermediate; H, high; PIT, Prognostic Index for peripheral T-cell lymphoma; ALC, absolute lymphocyte count; OS, overall survival; PFS, progression free survival.